机构：[1]Department of Medical Imaging, Guangzhou Nansha Central Hospital, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province 510150, People’s Republic of China[2]Department of Radiology, Guangdong Provincial Traditional Chinese Medicine Hospital & Postdoctoral Mobile Research Station of Guangzhou University of Traditional Chinese Medicine, 111 Da De Lu,Guangzhou,Guangdong Province 510120, People’s Republic of China大德路总院影像科大德路总院放射科广东省中医院[3]MRI Lab, Biomedical Engineering School of the Southern Medical University, Guangzhou City, Guangdong Province, China 510515 e-mail: shermanxinxuegang@126.com[4]Bernard and Irene Schwartz Center for Biomedical Imaging, New York University School of Medicine, New York, NY 10016, USA
The aim of this study is to perform a meta-analysis to evaluate the diagnostic performance of the in vivo post-contrast proton magnetic resonance spectroscopy (MRS) for benign/malignant discrimination of focal breast lesions. Sixteen studies with a total of 661 malignant breast lesions and 388 benign breast lesions were included. The pooled sensitivity and specificity of post-contrast 1H-MRS were 74 % (95 % confidence interval (CI) 70-77 %) and 78 % (95 % CI 7382 %), respectively. The positive likelihood ratio (PLR) and the negative likelihood ratio (NLR) were 4.00 (95 % CI 2.74-5.84) and 0.25 (95 % CI 0.17-0.37), respectively. From the fitted summary receiver operating characteristics curve (SROC), the AUC and Q* index were 0.89 and 0.83. Publication bias was present (t=2.43, P=0.029). Meta-regression analysis suggested that neither threshold effect nor evaluated covariates including method of choline analysis, strength of field, pulse sequence, repetition time (TR), and time interval were sources of heterogeneity (all P values >0.05). In vivo post-contrast 1H-MRS was useful for differentiation between malignant and benign focal breast lesions. However, pooled diagnostic measures might be overestimated. The standardization of the acquisition protocol as well as the post-processing method for post-contrast proton MRS need to be established for the future study.
基金：
National
Natural Science Foundation of China (No. 61172034), the Science
Foundation of Guangdong Province for Dr. Startup Project (No.
S2012040006618), and the Science and Technology Program of Guangzhou,
China (No.2014J4100160).
第一作者机构：[1]Department of Medical Imaging, Guangzhou Nansha Central Hospital, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province 510150, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构：[3]MRI Lab, Biomedical Engineering School of the Southern Medical University, Guangzhou City, Guangdong Province, China 510515 e-mail: shermanxinxuegang@126.com[4]Bernard and Irene Schwartz Center for Biomedical Imaging, New York University School of Medicine, New York, NY 10016, USA
推荐引用方式(GB/T 7714)：
Tan Jieying,Xu Li,Yao Wenqing,et al.In vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis[J].TUMOR BIOLOGY.2015,36(1):345-352.doi:10.1007/s13277-014-2635-0.
APA：
Tan, Jieying,Xu, Li,Yao, Wenqing,Wan, Yun,Zhou, Shuqin&Xin, Sherman Xuegang.(2015).In vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis.TUMOR BIOLOGY,36,(1)
MLA：
Tan, Jieying,et al."In vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis".TUMOR BIOLOGY 36..1(2015):345-352
